Fig. 2: Vaccine-elicited antibody HmAb64 targets the CD4-binding site and neutralizes tier-2 HIV-1 strains. | Nature Communications

Fig. 2: Vaccine-elicited antibody HmAb64 targets the CD4-binding site and neutralizes tier-2 HIV-1 strains.

From: Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains

Fig. 2

a HmAb64 binding to gp120 Env proteins. HmAb64 showed strong binding to wild-type gp120 antigens from multiple HIV-1 isolates but not to their D368R mutants, indicating CD4-binding site specificity. Data are presented as mean values ± SEM (n = 2 duplicated wells). b Neutralization breadth. HmAb64 neutralized 20 viruses (10%) from diverse clades of the 208-strain NIAID panel. c Neutralization titers (IC50) and tier designation of VRC panel viruses neutralized by HmAb64. d Number and percentage in each tier designation of VRC panel viruses neutralized by HmAb64. Source data are provided as a Source Data file.

Back to article page